-

Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.

Dr. Quigley joins Gilead from Bristol-Myers Squibb, where most recently he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center and Site Head of the Redwood City, California location. In that role, Dr. Quigley was responsible for setting strategy for Bristol-Myers Squibb’s oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies. He received a PhD in Immunology from Duke University and conducted his post-doctoral research at the Dana Farber Cancer Institute, Department of Pediatric Oncology. Dr. Quigley will report to William Lee, PhD, Executive Vice President of Research.

The company also announced that Linda Higgins, PhD, has recently taken on the role of Senior Vice President and Head of External Innovation. Dr. Higgins joined Gilead in 2010, leading a significant expansion of the company’s Biology organization that included the establishment of Biologics and Biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups. Under Dr. Higgins’ leadership, the Biology organization supported the discovery and development of eight marketed products and the advancement of more than 30 compounds into development. Dr. Higgins holds a PhD from the University of California, San Diego and conducted her post-doctoral research at the University of California, Berkeley. She will continue to report to Dr. Lee.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented Dr. Lee. “These appointments strengthen our research discovery organization and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Chris Ridley, Media
(650) 235-2220

Douglas Maffei, Investors
(650) 522-2739

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English

Contacts

Chris Ridley, Media
(650) 235-2220

Douglas Maffei, Investors
(650) 522-2739

More News From Gilead Sciences, Inc.

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent for patients who are not candidates f...

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (...

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. “This filing reflects Gilead’s continued commitment to advancin...
Back to Newsroom